Jefferies ...Thanks Benny ... for the heads-up.
Jefferies analyst Raj Denhoy initiated coverage of Profound Medical with a Buy rating and C$31 price target. Profound's TULSA-PRO can serve a "large and largely underserved group" in prostate treatment, namely men with benign disease for whom current technologies are not optimized, said Denhoy. He currently projects $C108M in global revenue by 2024 to supports an initial price target of $C31, but with routine reimbursement, both site adoption and utilization should be much higher, said Denhoy. Using a steeper adoption model would push his target to an upside of C$57, the analyst added.
Read more at:
https://thefly.com/n.php?id=3160419